FDA expands use of Zoryve to include young children with plaque psoriasis

3 months ago 12
The U.S. Food and Drug Administration has approved an expanded denotation for Zoryve (roflumilast) cream, 0.3%, for the topical attraction of plaque psoriasis successful patients ages 2 and older. The expanded support was granted to Arcutis Biotherapeutics.
Read Entire Article